Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they are...

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect

A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Older migrants' integration : an open dynamic model].

Revue medicale suisse·2026

Same author

Mixed-methods, participatory action research study exploring palliative and end-of-life care for LGBTIQ+ people in Switzerland: a protocol for the TRUST-PALL study.

BMJ open·2026

Same author

Barriers, Resources and Reserves Shaping Older Migrants' Access to Healthcare: A Research Imperative for Switzerland.

International journal of public health·2025

Same author

Intrasubject reproducibility of supine norepinephrine plasma concentrations in patients with cardiovascular sympathetic failure.

Autonomic neuroscience : basic & clinical·2024

Same author

Internet Use as a Moderator of the Relationship Between Personal Resources and Stress in Older Adults: Cross-Sectional Study.

JMIR aging·2024

Same author

Fingerprick volumetric absorptive microsampling for therapeutic drug monitoring of antiseizure medications: Reliability and real-life feasibility in epilepsy patients.

Journal of pharmaceutical and biomedical analysis·2024

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Pharmacokinetics of levodopa.

Manuela Contin¹, Paolo Martinelli

¹Department of Neurological Sciences, Neurology Clinic, University of Bologna, Bologna, Italy. manuela.contin@unibo.it

Journal of Neurology

|November 17, 2010

Summary

This review examines levodopa pharmacokinetics in Parkinson's disease (PD), highlighting how drug absorption and brain delivery impact treatment effectiveness. Strategies to manage fluctuations and improve therapeutic outcomes are discussed.

Area of Science:

Pharmacology
Neuroscience
Clinical Pharmacy

Background:

Levodopa is a primary treatment for Parkinson's disease (PD).
Its efficacy is significantly influenced by peripheral pharmacokinetics and disease progression.
Understanding levodopa's concentration-effect relationship is crucial for optimizing PD management.

Purpose of the Study:

To review clinically relevant determinants of levodopa peripheral pharmacokinetics in PD.
To discuss changes in the levodopa concentration-effect relationship as PD progresses.
To briefly outline strategies for optimizing levodopa pharmacokinetics and pharmacodynamics.

Main Methods:

Review of existing literature on levodopa pharmacokinetics and pharmacodynamics in Parkinson's disease.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jun 6, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Analysis of factors affecting levodopa absorption, distribution, and metabolism.

Discussion of clinical strategies for managing levodopa therapy.

Main Results:

Levodopa undergoes extensive presystemic metabolism and is absorbed via a saturable transport system.
Short plasma half-life leads to concentration fluctuations and therapeutic response swings ('wearing-off').
Advanced PD stages can involve negative levodopa effects at low or high plasma concentrations, complicating management.

Conclusions:

Optimizing levodopa therapy requires careful consideration of meal timing and dietary protein intake.
Strategies like liquid solutions and controlled-release formulations offer partial success.
Complex alterations in cerebral levodopa kinetics in advanced PD remain a challenge.